Empfehlungen zur Malariaprophylaxe

Key words

travel medicine - malaria - repellents - chemoprophylaxis - pediatric travelers - pregnant travelers

Publication History

Article published online:
07 August 2024

• Literatur

• 1 World Health Organization. World Malaria Report 2023. Geneva: WHO; 2023: 356
• 2 Falkenhorst G, RKI, Persönliche Kommunikation
• 3 Falkenhorst G, Enkelmann J, Faber M. et al Zur Situation bei wichtigen Infektionskrankheiten – Importierte Infektionskrankheiten 2022. Epid Bull 2023; 46: 3-20 DOI: 10.25646/11768.2.
• 4 Schlabe S, Reiter-Owona I, Nordmann T. et al Rapid diagnostic test negative Plasmodium falciparum malaria in a traveller returning from Ethiopia. Malar J 2021; 20: 145 DOI: 10.1186/s12936-021-03678-2.
• 5 Parr JB, Verity R, Doctor SM. et al Pfhrp2-Deleted Plasmodium falciparum Parasites in the Democratic Republic of the Congo: A National Cross-sectional Survey. J Infect Dis 2017; 216: 36-44 DOI: 10.1093/infdis/jiw538.
• 6 Plucinski MM, Herman C, Jones S. et al Screening for Pfhrp2/3-Deleted Plasmodium falciparum, Non-falciparum, and Low-Density Malaria Infections by a Multiplex Antigen Assay. J Infect Dis 2019; 219: 437-447 DOI: 10.1093/infdis/jiy525.
• 7 Feleke SM, Reichert EN. Mohammed, et al Plasmodium falciparum is evolving to escape malaria rapid diagnostic tests in Ethiopia. Nat Microbiol 2021; 06: 1289-1299 DOI: 10.1038/s41564-021-00962-4.
• 8 World Health Organization. Malaria Threats Map. Im Internet www.who.int/teams/global-malaria-programme/surveillance/malaria-threats-map
• 9 Whittaker C, Hamlet A, Sherrard-Smith E. et al Seasonal dynamics of Anopheles stephensi and its implications for mosquito detection and emergent malaria control in the Horn of Africa. Proc Natl Acad Sci U S A 2023; 120: e2216142120 DOI: 10.1073/pnas.2216142120.
• 10 Sinka ME, Pironon S, Massey NC. et al A new malaria vector in Africa: Predicting the expansion range of Anopheles stephensi and identifying the urban populations at risk. Proc Natl Acad Sci U S A 2020; 117: 24900-24908 DOI: 10.1073/pnas.2003976117.
• 11 Benz U, Traore MM, Revay EE. et al Effect of textile colour on vector mosquito host selection: a simulated field study in Mali, West Africa. J Travel Med 2024; 31: taae049 DOI: 10.1093/jtm/taae049.
• 12 Fradin MS.. Insect Protection. In: Keystone JS, Kozarsky PE, Connor BA, Nothdurft HD, Mendelson M, Leder K (eds.). Travel Medicine. 4th ed.: Elsevier. 2019: 43-52
• 13 The Medical Letter Inc. Insect Repellents. Insect Repellents. The Medical Letter on Drugs and Therapeutics 2019; 61: Issue 1579
• 14 Chiodini PL, Patel D, Goodyer L, Ranson H. Guidelines for malaria prevention in travellers from the United Kingdom 2022. London: Public Health England 2022
• 15 Lupi E, Hatz C, Schlagenhauf P. The efficacy of repellents against Aedes, Anopheles, Culex and Ixodes spp. – a literature review. Travel Med Infect Dis 2013; 11: 374-411 DOI: 10.1016/j.tmaid.2013.10.005.
• 16 Maiteki-Sebuguzi C, Gonahasa S, Kamya MR. et al Effect of long-lasting insecticidal nets with and without piperonyl butoxide on malaria indicators in Uganda (LLINEUP): final results of a cluster-randomised trial embedded in a national distribution campaign. Lancet Infect Dis 2023; 23: 247-258 DOI: 10.1016/S1473-3099(22)00469-8.
• 17 Ferrara P, Masuet-Aumatell C, Agüero F. et al Stand-by emergency treatment (SBET) of malaria in Spanish travellers: a cohort study. Malar J 2018; 17: 134 DOI: 10.1186/s12936-018-2304-7.
• 18 Ferrara P, Masuet-Aumatell C, Agüero F. et al The use of stand-by emergency treatment (SBET) for malaria in travellers: A systematic review and meta-analysis of observational studies. J Infect 2018; 77: 455-462 DOI: 10.1016/j.jinf.2018.09.007.
• 19 Tan R, Elmers J, Genton B. Malaria standby emergency treatment (SBET) for travellers visiting malaria endemic areas: a systematic review and meta-analysis. J Travel Med 2019; 26: taz027 DOI: 10.1093/jtm/taz027.
• 20 Vinnemeier CD, Rothe C, Kreuels B. et al Response to fever and utilization of standby emergency treatment (SBET) for malaria in travellers to Southeast Asia: a questionnaire-based cohort study. Malar J 2017; 16: 44 DOI: 10.1186/s12936-017-1678-2.
• 21 Reinsberg F, Moehlmann MW, Krumkamp R. et al Symptoms of illness during travel and risk factors for non-adherence to malaria prophylaxis-a cross-sectional study in travellers from Germany. J Travel Med 2023; 30: taad055 DOI: 10.1093/jtm/taad055.
• 22 Goetze S, Hiernickel C, Elsner P. Phototoxicity of Doxycycline: A Systematic Review on Clinical Manifestations, Frequency, Cofactors, and Prevention. Skin Pharmacol Physiol 2017; 30: 76-80 DOI: 10.1159/000458761.
• 23 Davis AE, Kennelley GE, Amaye-Obu T. et al The phenomenon of phototoxicity and long-term risks of commonly prescribed and structurally diverse drugs. J Photochem Photobiol 2024; 19: 100221 DOI: 10.1016/j.jpap.2023.100221.
• 24 Gaillard T, Briolant S, Madamet M. et al The end of a dogma: the safety of doxycycline use in young children for malaria treatment. Malar J 2017; 16: 148 DOI: 10.1186/s12936-017-1797-9.
• 25 Chelapharm. Educational Material Lariam® – Behördlich beauflagtes Schulungsmaterial für medizinisches Fachpersonal lür Lariam® 250 mg Tablette. Im Internet https://www.cheplapharm.com/educational-material/lariam/
• 26 Zoller T, Junghanss T, Kapaun A. et al Intravenous artesunate for severe malaria in travelers, Europe. Emerg Infect Dis 2011; 17: 771-777 DOI: 10.3201/eid1705.101229.
• 27 Kurth F, Lingscheid T, Steiner F. et al Hemolysis after Oral Artemisinin Combination Therapy for Uncomplicated Plasmodium falciparum Malaria. Emerg Infect Dis 2016; 22: 1381-1386 DOI: 10.3201/eid2208.151905.
• 28 Froeschl G, Nothdurft HD, von Sonnenburg F. et al Retrospective clinical case series study in 2017 identifies Plasmodium knowlesi as most frequent Plasmodium species in returning travellers from Thailand to Germany. Euro Surveill 2018; 23: 1700619 DOI: 10.2807/1560-7917.ES.2018.23.29.1700619.
• 29 Schwartz E, Parise M, Kozarsky P. et al Delayed onset of malaria – implications for chemoprophylaxis in travelers. N Engl J Med 2003; 349: 1510-1516 DOI: 10.1056/NEJMoa021592.
• 30 Baird JK. Tafenoquine for travelers’ malaria: evidence, rationale and recommendations. J Travel Med 2018; 25: tay110 DOI: 10.1093/jtm/tay110.
• 31 Chu CS, Freedman DO. Tafenoquine and G6PD: a primer for clinicians. J Travel Med 2019; 26: taz023 DOI: 10.1093/jtm/taz023.
• 32 Pays JF. Threats to the Effectiveness of Malaria Treatment. Bull Soc Pathol Exot 2018; 111: 197-198 DOI: 10.3166/bspe-2018-0046.
• 33 Ashley EA, Pyae Phyo A, Woodrow CJ. Malaria. Lancet 2018; 391: 1608-1621 DOI: 10.1016/S0140-6736(18)30324-6.
• 34 Grobusch MP, Kremsner PG. Uncomplicated malaria. Curr Top Microbiol Immunol 2005; 295: 83-104
• 35 Wilson ME, Weld LH, Boggild A. et al Fever in returned travelers: results from the GeoSentinel Surveillance Network. Clin Infect Dis 2007; 44: 1560-1568 DOI: 10.1086/518173.
• 36 DTG. Leitlinie: Diagnostik und Therapie der Malaria. Version Februar 2021. In: AWMF (ed.). 2021
• 37 Froeschl G, Beissner M, Huber K. et al Plasmodium knowlesi infection in a returning German traveller from Thailand: a case report on an ermerging malaria pathogen in a popular low-risk travel destination. BMC Infect Dis 2018; 18: 148 DOI: 10.1186/s12879-018-3059-z.
• 38 Irvine MH, Einarson A, Bozzo P. Prophylactic use of antimalarials during pregnancy. Can Fam Physician 2011; 57: 1279-1281
• 39 Embryotox.de. Doxycyclin. Im Internet https://www.embryotox.de/arzneimittel/details/ansicht/medikament/doxycyclin
• 40 World Health Organization. WHO Guidelines for malaria. WHO Global Malaria Programme 16 October 2023
• 41 University of Liverpool. Interaction Checker. Im Internet https://www.hiv-druginteractions.org/
• 42 Seeärztlicher Dienst. Merkblatt über Malaria. Stand: 03.2021. Dienststelle Schiffssicherheit der BG Verkehr, Hamburg
• 43 World Health Organization Malaria vaccine: WHO position paper – March 2022. Wkly Epid Rec 2022; 97: 61-80
• 44 Datoo MS, Dicko A, Tinto H. et al Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial. Lancet 2024; 403: 533-544 DOI: 10.1016/S0140-6736(23)02511-4..
• 45 Gaudinski MR, Berkowitz NM, Idris AH. et al A Monoclonal Antibody for Malaria Prevention. N Engl J Med 2021; 385: 803-814 DOI: 10.1056/NEJMoa2034031.
• 46 Lyke KE, Berry AA, Mason K. et al Low-dose intravenous and subcutaneous CIS43LS monoclonal antibody for protection against malaria (VRC 612 Part C): a phase 1, adaptive trial. Lancet Infect Dis 2023; 23: 578-588 DOI: 10.1016/S1473-3099(22)00793-9.
• 47 Kayentao K, Ongoiba A, Preston AC. et al Subcutaneous Administration of a Monoclonal Antibody to Prevent Malaria. N Engl J Med 2024; 390: 1549-1559 DOI: 10.1056/NEJMoa2312775.
• 48 Kayentao K, Ongoiba A, Preston AC. et al Safety and Efficacy of a Monoclonal Antibody against Malaria in Mali. N Engl J Med 2022; 387: 1833-1842 DOI: 10.1056/NEJMoa2206966.
• 49 World Health Organization. Countries with risk of yellow fever transmission and countries requiring proof of vaccination against yellow fever. (Revised on 3 January 2023). Im Internet https://cdn.who.int/media/docs/default-source/travel-and-health/countries-with-risk-of-yellow-fever-transmission.pdf
• 50 World Health Organization. Countries and territories certified malaria-free by WHO. Last update: 12 January 2024. Im Internet https://www.who.int/teams/global-malaria-programme/elimination/countries-and-territories-certified-malaria-free-by-whoint/teams/global-malaria-programme/elimination/countriesand-territories-certified-malaria-free-by-who